Roundtable Discussion: Untangling the Regulatory Landscape Surrounding Combination Therapies to Accelerate More Innovative Treatments Towards the Patients in Need
- Uncovering preclinical data and safety assessments required for combining a RAS inhibitor with another approved or unapproved drug
- How to overcome the regulatory hurdles associated with combining two unapproved drugs?
- Project Optimus: How much data is needed before dose selection for phase 3?